Literature DB >> 14519683

Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation.

Sara T Winokur1, Yi-Wen Chen, Peter S Masny, Jorge H Martin, Jeffrey T Ehmsen, Stephen J Tapscott, Silvere M van der Maarel, Yukiko Hayashi, Kevin M Flanigan.   

Abstract

The neuromuscular disorder facioscapulohumeral muscular dystrophy (FSHD) results from integral deletions of the subtelomeric repeat D4Z4 on chromosome 4q. A disruption of chromatin structure affecting gene expression is thought to underlie the pathophysiology. The global gene expression profiling of mature muscle tissue presented here provides the first insight into an FSHD-specific defect in myogenic differentiation. FSHD expression profiles generated by oligonucleotide microarrays were compared with those from normal muscle as well as other types of muscular dystrophies (DMD, aSGD) in order to determine FSHD-specific changes. In addition, matched biopsies (affected and unaffected muscle) from individuals with FSHD served to monitor expression changes during the progression of the disease as well as to diminish non-specific changes resulting from individual variability. Among genes altered in an FSHD-specific and highly significant manner, many are involved in myogenic differentiation and suggest a partial block in the normal differentiation program. Indeed, many of the transcripts affected in FSHD represent direct targets of the transcription factor MyoD. Additional mis-expressed genes confirm a diminished capacity to buffer oxidative stress, as demonstrated in FSHD myoblasts. This enhanced vulnerability of proliferative stage myoblasts to reactive oxygen species is also disease-specific, further implicating a defect in FSHD muscle satellite cells. Importantly, none of the genes localizing to the FSHD region at 4q35 were found to exhibit a significantly altered pattern of expression in FSHD muscle. This finding was corroborated by expression analysis of FSHD muscle using a custom cDNA microarray containing 51 genes and ESTs from the 4q35 region. Disruptions in FSHD myogenesis and oxidative capacity may therefore not arise from a position effect mechanism as has been previously suggested, but rather from a global effect on gene regulation. Improper nuclear localization of 4qter is discussed as an alternative model for FSHD gene regulation and pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14519683     DOI: 10.1093/hmg/ddg327

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  114 in total

1.  The Krüppel-like factor 15 as a molecular link between myogenic factors and a chromosome 4q transcriptional enhancer implicated in facioscapulohumeral dystrophy.

Authors:  Petr Dmitriev; Andrei Petrov; Eugenie Ansseau; Luiza Stankevicins; Sébastien Charron; Elena Kim; Tomas Jan Bos; Thomas Robert; Ahmed Turki; Frédérique Coppée; Alexandra Belayew; Vladimir Lazar; Gilles Carnac; Dalila Laoudj; Marc Lipinski; Yegor S Vassetzky
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  Chromatin loop domain organization within the 4q35 locus in facioscapulohumeral dystrophy patients versus normal human myoblasts.

Authors:  Andrei Petrov; Iryna Pirozhkova; Gilles Carnac; Dalila Laoudj; Marc Lipinski; Yegor S Vassetzky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

3.  Cytogenetic and immuno-FISH analysis of the 4q subtelomeric region, which is associated with facioscapulohumeral muscular dystrophy.

Authors:  Fan Yang; Chunbo Shao; Vettaikorumakankav Vedanarayanan; Melanie Ehrlich
Journal:  Chromosoma       Date:  2004-05-11       Impact factor: 4.316

4.  A unique library of myogenic cells from facioscapulohumeral muscular dystrophy subjects and unaffected relatives: family, disease and cell function.

Authors:  Sachiko Homma; Jennifer C J Chen; Fedik Rahimov; Mary Lou Beermann; Kendal Hanger; Genila M Bibat; Kathryn R Wagner; Louis M Kunkel; Charles P Emerson; Jeffrey Boone Miller
Journal:  Eur J Hum Genet       Date:  2011-11-23       Impact factor: 4.246

5.  FRG2, an FSHD candidate gene, is transcriptionally upregulated in differentiating primary myoblast cultures of FSHD patients.

Authors:  T Rijkers; G Deidda; S van Koningsbruggen; M van Geel; R J L F Lemmers; J C T van Deutekom; D Figlewicz; J E Hewitt; G W Padberg; R R Frants; S M van der Maarel
Journal:  J Med Genet       Date:  2004-11       Impact factor: 6.318

Review 6.  The D4Z4 repeat-mediated pathogenesis of facioscapulohumeral muscular dystrophy.

Authors:  Silvère M van der Maarel; Rune R Frants
Journal:  Am J Hum Genet       Date:  2005-01-24       Impact factor: 11.025

7.  Hybridization analysis of D4Z4 repeat arrays linked to FSHD.

Authors:  Melanie Ehrlich; Kesmic Jackson; Koji Tsumagari; Pilar Camaño; Richard J F L Lemmers
Journal:  Chromosoma       Date:  2006-11-28       Impact factor: 4.316

8.  Gene selection for multiclass prediction by weighted Fisher criterion.

Authors:  Jianhua Xuan; Yue Wang; Yibin Dong; Yuanjian Feng; Bin Wang; Javed Khan; Maria Bakay; Zuyi Wang; Lauren Pachman; Sara Winokur; Yi-Wen Chen; Robert Clarke; Eric Hoffman
Journal:  EURASIP J Bioinform Syst Biol       Date:  2007

9.  RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy.

Authors:  Lauren Snider; Amy Asawachaicharn; Ashlee E Tyler; Linda N Geng; Lisa M Petek; Lisa Maves; Daniel G Miller; Richard J L F Lemmers; Sara T Winokur; Rabi Tawil; Silvère M van der Maarel; Galina N Filippova; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2009-04-09       Impact factor: 6.150

10.  DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1.

Authors:  Manjusha Dixit; Eugénie Ansseau; Alexandra Tassin; Sara Winokur; Rongye Shi; Hong Qian; Sébastien Sauvage; Christel Mattéotti; Anne M van Acker; Oberdan Leo; Denise Figlewicz; Marietta Barro; Dalila Laoudj-Chenivesse; Alexandra Belayew; Frédérique Coppée; Yi-Wen Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.